Skyline Gin
Skeptic Distillery CO. — Melrose Park, IL
Illinois
About Skyline Gin
Skyline Gin is a vodka product originating from Illinois. According to TTB COLA records, the spirit is classified as vodka with an alcohol content between 80 and 89 proof. The brand maintains one distinct product offering currently tracked in the vodka category. TTB label approval records indicate a single approved label on file for this brand, with the most recent approval documented in 2024. The product is registered with the Alcohol and Tobacco Tax and Trade Bureau, establishing its compliance with federal spirits regulations and labeling requirements. Skyline Gin represents an entry in the American vodka market, with its Illinois origin placing it within the broader landscape of domestic spirit producers. The brand's registration in the TTB COLA system reflects its status as a commercially available vodka product meeting federal classification standards for spirits in the 80 to 89 proof category.
| Label Name | Spirit Type | Status | Approval Date | Producer | |
|---|---|---|---|---|---|
 | Skyline Gin VODKA 80-89 PROOF | Vodka 80-89 Proof | Approved | 2024-01-25 | Skeptic Distillery CO. |
Page 1 of 1
Skyline Gin at a Glance
Skyline Gin has 1 distinct product with 1 total TTB label approvals, including Vodka 80-89 Proof. Labels approved between 2024-01-25 and 2024-01-25. Produced in Illinois.
All information sourced from public TTB records.
Are you the owner or distributor of Skyline Gin?
Claim this brand listing to update information or get featured. Contact team@buy.vodka.
Produced At
Skeptic Distillery CO.Related Brands
- Dubbles also from Illinois
- Cucina Bella also from Illinois
- Fancy Pants also from Illinois
- Circle Tavern also from Illinois
- Spirit Water also from Illinois
- Muscle also makes Vodka 80-89 Proof
- Veil also makes Vodka 80-89 Proof
- Heritage Distilling CO also makes Vodka 80-89 Proof
- Svedka also makes Vodka 80-89 Proof
- Holla also makes Vodka 80-89 Proof
Related Questions
Browse All Labels
Stay informed
Newsletter coming soon.
Follow us on X for new approvals, launches, and industry intelligence.